Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Inv. presentation
Quarterly results
|
|
Sonnet BioTherapeutics Holdings, Inc. (BURG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/22/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
8-K
| Quarterly results |
| 06/30/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...|
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. Warrant Shares: [______] Issue Date: [______], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, [______] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized terms used and not otherwise defined her...",
"COMMON STOCK PURCHASE WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. Warrant Shares: [______] Issue Date: [______], 2023 Initial Exercise Date: [_______] 1 , 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [______] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on [______], 20[__] 2 but not thereafter, to subscribe for and purchase from Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 . Definitions . Capitalized term...",
"PLACEMENT AGENT WARRANT SONNET BIOTHERAPEUTICS HOLDINGS, INC. Warrant Shares: [______] Issue Date: [______], 2023 Initial Exercise Date: [______] 1 , 2023 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT certifies that, for value received, [______] or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on [______], 20[__] 2 but not thereafter, to subscribe for and purchase from Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation , up to [______] shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. This Warrant is being issued purs...",
"Sonnet BioTherapeutics Holdings, Inc. 100 Overlook Center, Suite 102 Princeton, New Jersey 08540",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of June 28, 2023, between Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , as to the Shares, the Prefunded Warrants and Prefunded Warrant Shares and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D promulgated thereunder as to the Common Warrants , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the ...",
"Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement" |
|
| 05/10/2023 |
8-K
| Quarterly results |
| 04/18/2023 |
8-K
| Quarterly results |
| 03/24/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
8-K
| Quarterly results |
| 01/19/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 01/09/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 12/15/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 11/02/2022 |
8-K
| Quarterly results |
| 11/01/2022 |
8-K
| Quarterly results |
| 10/31/2022 |
8-K
| Quarterly results |
| 10/17/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 10/04/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/29/2022 |
8-K
| Quarterly results |
| 09/21/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/19/2022 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
| 09/16/2022 |
8-K
| Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits &... |
| 08/25/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
| 08/15/2022 |
8-K
| Quarterly results |
| 06/23/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 04/11/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ...|
Docs:
|
"AMENDMENT TO The bylaws OF Sonnet BioTherapeutics Holdings, Inc. This Amendment to the Bylaws, as amended , of Sonnet BioTherapeutics Holdings, Inc., a Delaware corporation , has been adopted and approved by the Board of Directors of the Corporation on April 11, 2022 and is effective as of April 11, 2022. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Bylaws. 1. Article II, Section 5 is hereby amended to read as follows: Section 5. Quorum . The holders of a majority of the voting power of the stock issued and outstanding and entitled to vote at the meeting, whether present in person or represented by proxy, shall constitute a quorum at all meetings of the shareholders for the transaction of business, except as otherwise provided by s..." |
|
| 04/08/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 03/16/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/08/2022 |
8-K
| Quarterly results |
| 12/17/2021 |
8-K
| Quarterly results |
| 10/07/2021 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial ... |
| 08/31/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
|
|
|